Memantin Tad

Memantine Hydrochloride, the active ingredient in Memantin Tad, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer's disease in adult patients. GNH USA supplies Memantin Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantin Tad belongs to the NMDA receptor antagonist class and is used in the management of Alzheimer's disease. - Moderate Alzheimer's disease: helps maintain cognitive function and daily activities. - Severe Alzheimer's disease: supports functional abilities and may slow decline. - Alzheimer's disease with behavioral symptoms: may reduce agitation and improve overall patient behavior.

Memantin Tad may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Hypertension

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (rash, swelling, anaphylaxis) - Hallucinations or psychosis - Cardiac arrhythmias

When prescribing Memantin Tad, clinicians should consider several safety aspects. - Renal impairment: dose adjustment may be required. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: observe blood pressure and heart rate. - Concomitant NMDA antagonists: avoid combined use to reduce toxicity risk. - Pregnancy and lactation: use only if clearly needed, as safety data are limited. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Memantin Tad can interact with other medicines, necessitating careful review of a patient’s medication list.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can lead to severe CNS effects. - High‑dose NSAIDs: may exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Diuretics: potential for increased hypotension. - Antihypertensives: additive blood‑pressure lowering effect. - Anticholinergic agents: may diminish cognitive benefits of memantine. - CYP450 inhibitors: could alter memantine plasma concentrations.